In vitro and in vivo efficacy of a potentiated sulffonamide, Ro5–0037, for inhibition of Aeromonas salmonicida, causative agent of fish furunculosis was determined. The components of the potentiated sulfonamide, sulfadimethoxine, and ormetoprim were tested alone and in combination. In vitro results showed that both sulfonamide-resistant and sensitive strains of A. salmonicida had greater sensitivity to Ro5–0037 than to either of its components. Also, sulfonamide-sensitive strains developed resistance to ormetoprim and sulfadimethoxine more rapidly than to Ro5–0037. Efficacy studies with small numbers of artificially infected trout revealed that Ro5–0037 effectively controlled furunculosis at 50 mg/kg of fish/day, one fourth the usual sulfonamide dosage level. Extensive field trials also showed the 50 mg/kg level of Ro5–0037 gave effective control of hatchery outbreaks of furunculosis. As found in the in vitro studies, all in vivo trials indicated the combination of ormetoprim and sulfadimethoxine was more efficient in inhibiting A. salmonicida than either component alone.
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies
